Skip to main content Help with accessibility Skip to main navigation

UPADACITINIB prolonged-release tablets (RINVOQ®▼) for treating moderate to severe rheumatoid arthritis

CCG Approval Status:

Date Added: 24 - Feb - 2020
Body System:
Grey

The Pan Mersey Area Prescribing Committee does not currently recommend the prescribing of UPADACITINIB prolonged-release tablets (RINVOQ®▼) for treating moderate to severe rheumatoid arthritis.